glp-1 and surgery risk Bariatric or GLP-1's: Which weight loss treatment is right for you? If you're on a GLP-1

Executive Vice President & President, Lilly Cardiometabolic Health, Eli Lilly and Company Why this matters 1 Triple agonist = next-gen metabolic therapy Mimics GLP-1, GIP, and glucagon multi-pathway metabolic control 2 Diabetes + obesity convergence Simultaneous A1C + weight control = major unmet need solved 3 Competitive landscape shift Raises the bar vs GLP-1 mono & dual incretin therapies 4 No plateau signal is critical Suggests longer-term sustained efficacy Safety profile (expected class effects) Nausea, diarrhea, vomiting (dose-escalation phase) Discontinuation rates relatively low (25%) My takeaway 1 Metabolic disease treatment is entering multi-hormone era 2 Obesity + diabetes becoming one therapeutic category 3 Efficacy approaching bariatric-level outcomes 4 Sets new benchmark for Novo Nordisk and competitors Bottom line: Retatrutide isnt just competing Its redefining how we treat metabolic disease at the systems level #Diabetes #Obesity #GLP1 #Biotech #ClinicalTrials #Pharma #Innovation To view or add a comment, sign in 2,716 followers

In many cases, the posts start the same way: "We'd been trying for years." "I thought I couldn't get pregnant." "I was waiting to start fertility treatment." Then comes the surprise positive pregnancy test

( b ) body weight, fat mass and fat free mass at day 5

Biological Chemistry 398:261275 Fu D (2015) Yeast glutathione nutrition preparation

Antacids that contain aluminum, magnesium, or calcium are among the biggest offenders

Additionally, a subcutaneous injection uses a shorter needle because it does not need to go deep into the tissues